|Follow us :|
Luai Al Bakour
El Temamy Pharmacy
Akoni Hijyen Teknolojileri Sanayi ve Dış Ticaret LTD. ŞTİ
Britton Chance Center for Biomedical Photonics
Arabian Trade Center - ATC
Medical Facility (32206):
Legality International. (Pvt.) Ltd.
MainYou must sign in to use this servcie
Feedback - Please use the form below to send your query or comment
You must sign in to use this servcie
It is indicated for the treatment of intestinal parasitosis caused by the presence of acute or chronic intestinal amebiasis caused by Enterobius vermicularis (pinworm), Ascaris lumbricoides (worms), Trichuris trichiura (whipworm), Necator americanus, Ancylostoma duodenale (hookworm) , Strongyloides stercoralis, Taenia solium, Taenia saginata (tapeworm) and Hymenolepis nana. In patients living in endemic areas, regular treatment with AMOEBRIZ ® (3-4 times per year) can significantly reduce re-infection with a high level of clinical significance. Amebicide, intraluminal parasite.
It is contraindicated in people who have shown hypersensitivity to mebendazole or Quinfamide.Treatment of extraintestinal forms of amebiasis and other parasites.
AMOEBRIZ ® is generally well tolerated at the recommended dose. However, patients with high parasite load have expressed diarrhea or abdominal pain when treated with AMOEBRIZ ®.Post-marketing experience: Within each system, the adverse reactions are classified according to the report of frequency, using the following: Very common (> 1 / 10). Common (> 1 / 100, <1 / 10). Uncommon (> 1 / 1, 000, <1 / 100). Rare (> 1 / 10, 000, <1 / 1, 000). Very rare (<1 / 10, 000) including isolated reports. Lymphatic and blood: Very rare: neutropenia (with prolonged use persistently higher dose than recommended). Immune system: Very rare: hypersensitivity reactions including anaphylactic and anaphylactoid reaction. Nervous system: Very rare: convulsions in children. Gastrointestinal System: Very rare: abdominal pain, diarrhea (these symptoms are also the result of intestinal infection by itself). Hepatobiliary disorders: Very rare: hepatitis and abnormal liver function tests (with longer use persistently higher dose than recommended). Subcutaneous tissue and skin: Very rare: toxic epidermal necrolysis, Stevens-Johnson syndrome, rash, angioedema, urticaria, rash. Kidney and urinary system: Very rare: Glomerulonephritis (with prolonged use persistently higher dose than recommended) Has been associated with the use of Quinfamide headache, nausea, bloating and abdominal pain. Most of the time these effects have been mild and transient.
Concomitant treatment with cimetidine may inhibit the metabolism of mebendazole in the liver, resulting in increased plasma concentrations, especially in prolonged treatments.Therefore, we recommend the determination of these concentrations to allow dose adjustments. Avoid concomitant use of metronidazole or AMOEBRIZ ® and alcohol.
It recommends a single dose of treatment and avoid alcohol intake during the day of treatment. It does not alter the mental state or ability to drive. Do not use during pregnancy and lactation. No data on the combined use of mebendazole and Quinfamide during pregnancy or breastfeeding. Although absorption of both products is low, when prescribing AMOEBRIZ ® during pregnancy or lactation, should be weighed against the expected therapeutic benefits, particularly during the first trimester of pregnancy
Dosage and AdministrationYou must sign in to use this servcie
Technical DescriptionYou must sign in to use this servcie
Dr. Samer Al-Jneidy
Dr. Hani Najjar
Samir Moussa M.D.
Dr. Tahsin Martini
Dr . Dirar Abboud
Dr. Faisal Dibsi
Dr. Talal Sabouni
Yaser Habrawi , F.R.C.S.Ed